InvestSMART

Amplia Therapeutics Limited (ASX: ATX) - Announcements

Current share price for ATX : $0.150 0.005 (3.45%)+

ASX company news and announcements for Amplia Therapeutics Limited (ATX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Amplia Therapeutics Limited (ATX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Amplia Therapeutics Limited (ATX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Amplia Therapeutics Limited (ATX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$77 Proposed issue of securities - ATX 23 Jul 2025 9:53AM $0.285 $0.150 fallen by 47.37%
$77 Amplia announces A$25m Placement and Launches A$2.5m SPP 23 Jul 2025 9:53AM $0.285 $0.150 fallen by 47.37%
$77 Trading Halt 21 Jul 2025 9:13AM $0.285 $0.150 fallen by 47.37%
$77 Another Partial Response in ACCENT Pancreatic Cancer Trial 11 Jul 2025 9:00AM $0.320 $0.150 fallen by 53.13%
$77 Application for quotation of securities - ATX 4 Jul 2025 2:40PM $0.290 $0.150 fallen by 48.28%
$77 Annual General Meeting to be held Wednesday 27 August 2025 2 Jul 2025 5:11PM $0.250 $0.150 fallen by 40%
$77 Additional Partial Response in Pancreatic Cancer Trial 2 Jul 2025 9:42AM $0.235 $0.150 fallen by 36.17%
$77 Amplia Gains US Ethics Approval for Pancreatic Cancer Trial 24 Jun 2025 8:24AM $0.180 $0.150 fallen by 16.67%
$77 Change in substantial holding 19 Jun 2025 10:08AM $0.155 $0.150 fallen by 3.23%
$77 Second Complete Response in ACCENT Pancreatic Cancer Trial 19 Jun 2025 8:32AM $0.081 $0.150 risen by 85.19%
$77 Pathological Complete Response in Pancreatic Cancer Trial 16 Jun 2025 8:29AM $0.057 $0.150 risen by 163.16%
$77 Appendix 4G - Key to Corporate Governance Disclosures 30 May 2025 3:14PM $0.050 $0.150 risen by 200%
$77 2025 Corporate Governance Statement 30 May 2025 3:14PM $0.050 $0.150 risen by 200%
$77 Preliminary Final Report and Annual Report YE 31 March 2025 30 May 2025 3:13PM $0.050 $0.150 risen by 200%
$77 Change in substantial holding 16 May 2025 5:05PM $0.065 $0.150 risen by 130.77%
$77 ACCENT Trial Achieves Superiority over Chemotherapy Alone 15 May 2025 8:21AM $0.055 $0.150 risen by 172.73%
$77 Amplia Appoints Dr Jason Lickliter as Chief Medical Officer 12 May 2025 8:20AM $0.054 $0.150 risen by 177.78%
$77 Quarterly Activities/Appendix 4C Cash Flow Report 30 Apr 2025 8:28AM $0.053 $0.150 risen by 183.02%
$77 ACCENT Data Update Presented at International Conference 28 Apr 2025 10:24AM $0.051 $0.150 risen by 194.12%
$77 US Clinical Trial Activities for Narmafotinib Now Underway 9 Apr 2025 8:20AM $0.054 $0.150 risen by 177.78%
$77 Encouraging Updated Data from Pancreatic Cancer Trial 27 Mar 2025 8:15AM $0.070 $0.150 risen by 114.29%
$77 Type D Meeting Outcome With US Food And Drug Administration 3 Mar 2025 8:18AM $0.078 $0.150 risen by 92.31%
$77 Listing Rule 3.11.2 - change of Exercise Price of Options 13 Feb 2025 5:13PM $0.079 $0.150 risen by 89.87%
$77 Completion of Recruitment of ACCENT Trial 31 Jan 2025 9:03AM $0.081 $0.150 risen by 85.19%
$77 Quarterly Activities/Appendix 4C Cash Flow Report 30 Jan 2025 10:21AM $0.083 $0.150 risen by 80.72%

76 - 100 of 528 results

Page 4 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.